Business
Update on AWKN-SDN-14 programme
Update on AWKN-SDN-14 programme.
About this update from Solvonis Therapeutics Plc
[{"type":"text","content":"\n\nTHIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF EU REGULATION 596/2014 AS IT FORMS PART OF DOMESTIC LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INSIDE INFORMATION WILL BE CONSIDERED TO BE IN THE PUBLIC DOMAIN.\n \n 18 March 2025\nSolvonis Therapeutics plc\n(\"Solvonis\" or the \"Company\")\nUpdate on AWKN-SDN-14 programme, including the appointment of Evotec SE (\"Evotec\") to progress preclinical testing\n \nSolvonis Therapeutics plc (LSE: SVNS), an innovative biotechnology company co-developing therapeutics for mental health disorders, provides an update on its collaboration with Awakn Life Sciences Corp. (\"Awakn\"). The collaboration is focused on developing next-generation treatments for trauma-related mental health disorders, such as Post-Traumatic Stress Disorder (\"PTSD\"), which affects approximately 13 million adults in the U.S. and which the Company estimates affects 20 million in the US, the UK, and other key EU markets.\nAWKN-SDN-14 programme overview\nThe AWKN-SDN-14 programme (the \"Programme\") is dedicated to developing a novel pro-social drug candidate, with the potential for an improved safety profile compared to existing investigational PTSD treatments. By enhancing trust, empathy, and social bonding, being critical elements in PTSD therapy, AWKN-SDN-14 aims to help individuals rebuild relationships, overcome isolation and engage more effectively in treatment.\nThe drug candidate is designed to modulate neurotransmitter activity, specifically enhancing the release of Serotonin (\"SERT\"), Dopamine (\"DAT\"), and Noradrenaline (\"NET\").\nThe key initial stages of the Programme include:\n1. Preclinical drug discovery\n2. Intellectual property protection\n3. Synthesis of development candidates\n4. In-vitro screening for SERT, DAT, and NET re-absorption inhibition\n5. In-vitro screening for SERT, DAT, and NET release\n6. Preclinical animal testing\n7. Lead candidate selection\nProgress and updates\n1. Preclinical drug discovery.\nThis phase was successfully completed by Prof. David Nu...